/PTPI
PTPI Stock - Petros Pharmaceuticals, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$0.01-25.00%
$0.00 (-25.00%) • Dec 19
45
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.51
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PTPI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.01 – $0.01
TARGET (TP)$0.01
STOP LOSS$0.01
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.72
52W High$16.25
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.11M | $5.82M | $5.99M | $7.81M | $9.56M |
| Gross Profit | $3.90M | $4.19M | $3.70M | $6.21M | $5.51M |
| Gross Margin | 76.3% | 72.0% | 61.8% | 79.5% | 57.7% |
| Operating Income | $-17,679,650 | $-13,617,364 | $-19,915,749 | $-18,048,016 | $-17,282,039 |
| Net Income | $-14,318,790 | $-8,163,188 | $-20,037,573 | $-8,986,676 | $-20,585,925 |
| Net Margin | -280.1% | -140.2% | -334.4% | -115.0% | -215.3% |
| EPS | $-3.34 | $-6.35 | $-9.68 | $-8.25 | $-38.55 |
Company Overview
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PTPIBeat Rate
0%
Last 5 quarters
Avg Surprise
-5974.1%
EPS vs Estimate
Beats / Misses
0/5
Last 12 quarters
Latest EPS
$-0.03
Q4 2025
EPS Surprise History
Q2 24
-3459.0%
$-51.25vs$-1.44
Q2 24
No data
Q3 24
-1101.3%
$-9.25vs$-0.77
Q4 24
-4469.0%
$-13.25vs$-0.29
Q1 25
-251.5%
$-29.00vs$-8.25
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 13, 2025 | — | $-0.03 | — | — |
Q3 2025 | Aug 14, 2025 | — | $-1.58 | — | — |
Q2 2025 | May 15, 2025 | — | $-8.46 | — | — |
Q1 2025 | Mar 31, 2025 | $-8.25 | $-29.00 | -251.5% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.29 | $-13.25 | -4469.0% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.77 | $-9.25 | -1101.3% | ✗ MISS |
Q2 2024 | May 31, 2024 | — | $0.13 | — | — |
Q2 2024 | May 15, 2024 | $-1.44 | $-51.25 | -3459.0% | ✗ MISS |
Q4 2023 | Nov 15, 2023 | — | $-57.75 | — | — |
Q3 2023 | Aug 14, 2023 | — | $-30.00 | — | — |
Q2 2023 | May 15, 2023 | — | $-16.50 | — | — |
Q2 2023 | Apr 7, 2023 | — | $-7.20 | — | — |
Q4 2022 | Nov 15, 2022 | — | $-167.50 | — | — |
Q3 2022 | Aug 15, 2022 | — | $-22.50 | — | — |
Q2 2022 | May 16, 2022 | — | $-2.50 | — | — |
Q2 2022 | Apr 1, 2022 | — | $-180.00 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-42.50 | — | — |
Q3 2021 | Aug 17, 2021 | — | $-112.50 | — | — |
Q2 2021 | May 17, 2021 | $-0.29 | $-60.00 | -20589.7% | ✗ MISS |
Q1 2021 | Mar 12, 2021 | — | $-4.92 | — | — |
Frequently Asked Questions about PTPI
What is PTPI's current stock price?
Petros Pharmaceuticals, Inc. (PTPI) is currently trading at $0.01 per share. The stock has moved -25.00% today.
What is the analyst price target for PTPI?
No analyst price targets are currently available for this stock.
What sector is Petros Pharmaceuticals, Inc. in?
Petros Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is PTPI's market cap?
Petros Pharmaceuticals, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does PTPI pay dividends?
No, Petros Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCCM
Concord Medical Services Holdings Limited
$4.15
Mkt Cap: $0.0B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
HEPA
Hepion Pharmaceuticals, Inc.
$0.07
Mkt Cap: $0.0B
IVF
INVO Fertility, Inc.
$0.33
Mkt Cap: $0.0B
LIXT
Lixte Biotechnology Holdings, Inc.
$4.32
Mkt Cap: $0.0B
PETV
PetVivo Holdings, Inc.
$1.16
Mkt Cap: $0.0B
PKBO
Peak Bio, Inc.
$0.02
Mkt Cap: $0.0B
SISI
Shineco, Inc.
$0.38
Mkt Cap: $0.0B
SYRA
Syra Health Corp. Class A Common Stock
$0.11
Mkt Cap: $0.0B
XAGE
Longevity Health Holdings Inc.
$0.43
Mkt Cap: $0.0B
Explore stocks similar to PTPI for comparison